Research Article
Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis
Figure 2
In vivo efficacy of butenafine and nanoenabled formulations in experimental cutaneous leishmaniasis. BALB/c mice were infected into the base of the tail with 106 promastigote forms of L. (L.) amazonensis in stationary phase of growth. Four weeks after, infected animals were topically treated once daily for 15 days with blank SNEDDS, blank SNEDDS gel, BUT-SNEDDS, BUT-SNEDDS gel, butenafine, and Glucantime. Lesion sizes were analyzed weekly (a), and the skin parasitism from the base of tail, quantified by limiting dilution assay, was analyzed at 8 weeks of postinfection (b). indicates statistical significance. G1: infected control; G2 and G3: animals treated with blank SNEDDS or blank SNEDDS gels, respectively; G4: animals treated with BUT-SNEDDS; G5: animals treated BUT-SNEDDS gel; G6: animals treated with butenafine; G7: animals treated with Glucantime.
| (a) |
| (b) |